<DOC>
	<DOCNO>NCT02902991</DOCNO>
	<brief_summary>Through prospective clinical trial , investigator focus relationship circulate tumor biomarkers ( i.e . circulate tumor cell , circulate tumor DNA biomarkers ) status primary tumor discus application assess prognosis individualize therapeutic direction . Moreover , relationship circulate tumor cell subpopulation base epithelial-mesenchymal transition molecular pathological classification breast cancer determine , may enable determination value application therapeutic decision making .</brief_summary>
	<brief_title>The Study Clinical Utility Liquid Biopsy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female patient age â‰¥18 year histologically confirm breast cancer . The patient diagnose breast cancer first time , include postoperative patient within one month patient diagnose Stage IV breast cancer first time . The patient begin medication breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>liquid biopsy , breast cancer , circulate tumor biomarker</keyword>
</DOC>